HLB Group Chairman Jin Yang-gon and Affiliate CEOs Purchase Company Shares

Jin Yang-gon, Chairman of the HLB Group, purchased 34,081 shares of HLB Therapeutics on the market on July 20, and between July 20 and 21, he also acquired 50,428 shares of HLB Genex and 58,000 shares of HLB Panagen, respectively, through on-market transactions.

According to the HLB Group on July 22, Chairman Jin has purchased over 1.1 million shares of the group's affiliates on the market this year alone, across 50 separate transactions.

Brian Kim, CEO of HLB Innovation, additionally purchased 15,000 shares of the company on July 20. With this latest purchase, CEO Kim increased his total HLB Innovation holdings to 1,633,323 shares.

Jang In-geun, CEO of HLB Panagen, purchased 3,000 shares of HLB Panagen on July 15. Over the course of three on-market transactions this year, CEO Jang bought an additional 7,000 shares, raising his holdings from 10,000 shares to 17,000 shares.

Kim Do-yeon, CEO of HLB Genex, bought 32,567 shares of the company on July 13 through an on-market purchase. Since the beginning of the year, CEO Kim has purchased a total of 79,538 shares over four transactions, thereby increasing his total holdings to 92,248 shares.

An HLB Group representative stated, "The recent decline in share prices is largely unrelated to the business competitiveness or the mid- to long-term growth potential of our group affiliates. The voluntary share-buying by company management demonstrates their commitment to responsible management that does not waver in the face of short-term market fluctuations and their determination to enhance both corporate value and shareholder value."

This content was produced with the assistance of AI translation services.